Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.

Also called NCT07493304

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07493304
  • EU CT 2024-519299-16-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Bulgaria, Japan, Romania, South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07493304. Randomized; no masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2031-07-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Acronym
ROXI-CAT-II
Condition
Venous Thromboembolism (VTE)
Intervention (Drug)
REGN7508
Intervention (Drug)
Apixaban
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07493304
Content hash
515a4bab0362708a3fb8e94235ef397e79666787463250e2d68cb6deee705f5c